nodes	percent_of_prediction	percent_of_DWPC	metapath
Metronidazole—CYP3A4—Thiotepa—urinary bladder cancer	0.121	0.253	CbGbCtD
Metronidazole—CYP2C8—Fluorouracil—urinary bladder cancer	0.0968	0.202	CbGbCtD
Metronidazole—CYP2C8—Etoposide—urinary bladder cancer	0.0808	0.169	CbGbCtD
Metronidazole—CYP2C9—Fluorouracil—urinary bladder cancer	0.0675	0.141	CbGbCtD
Metronidazole—CYP2C9—Cisplatin—urinary bladder cancer	0.0574	0.12	CbGbCtD
Metronidazole—CYP3A4—Etoposide—urinary bladder cancer	0.0328	0.0685	CbGbCtD
Metronidazole—CYP3A4—Doxorubicin—urinary bladder cancer	0.0223	0.0467	CbGbCtD
Metronidazole—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00229	0.0558	CbGpPWpGaD
Metronidazole—CYP2C8—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00197	0.0481	CbGpPWpGaD
Metronidazole—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00161	0.0391	CbGpPWpGaD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0016	0.039	CbGpPWpGaD
Metronidazole—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00153	0.0373	CbGpPWpGaD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0013	0.0317	CbGpPWpGaD
Metronidazole—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00125	0.0303	CbGpPWpGaD
Metronidazole—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0012	0.0292	CbGpPWpGaD
Metronidazole—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00106	0.0258	CbGpPWpGaD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000984	0.024	CbGpPWpGaD
Metronidazole—CYP2C8—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000888	0.0216	CbGpPWpGaD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000859	0.0209	CbGpPWpGaD
Metronidazole—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000767	0.0187	CbGpPWpGaD
Metronidazole—CYP2C8—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000757	0.0184	CbGpPWpGaD
Metronidazole—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000755	0.0184	CbGpPWpGaD
Metronidazole—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000723	0.0176	CbGpPWpGaD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.000649	0.0158	CbGpPWpGaD
Metronidazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000624	0.0152	CbGpPWpGaD
Metronidazole—CYP2C8—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000622	0.0152	CbGpPWpGaD
Metronidazole—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000616	0.015	CbGpPWpGaD
Metronidazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000506	0.0123	CbGpPWpGaD
Metronidazole—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000504	0.0123	CbGpPWpGaD
Metronidazole—CYP2C8—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000472	0.0115	CbGpPWpGaD
Metronidazole—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000463	0.0113	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—GSTZ1—urinary bladder cancer	0.000423	0.0103	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000417	0.0102	CbGpPWpGaD
Metronidazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000412	0.01	CbGpPWpGaD
Metronidazole—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000406	0.0099	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—GSTO2—urinary bladder cancer	0.000401	0.00977	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—NAT1—urinary bladder cancer	0.000401	0.00977	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000396	0.00964	CbGpPWpGaD
Metronidazole—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000384	0.00936	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.000367	0.00894	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000362	0.00882	CbGpPWpGaD
Metronidazole—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000355	0.00864	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000344	0.00839	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00034	0.00827	CbGpPWpGaD
Metronidazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000334	0.00813	CbGpPWpGaD
Metronidazole—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000333	0.0081	CbGpPWpGaD
Metronidazole—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.00033	0.00805	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000327	0.00795	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000327	0.00795	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000326	0.00794	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000322	0.00784	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.000299	0.00727	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000295	0.00717	CbGpPWpGaD
Metronidazole—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000286	0.000595	CcSEcCtD
Metronidazole—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000286	0.000595	CcSEcCtD
Metronidazole—Hepatitis—Methotrexate—urinary bladder cancer	0.000284	0.000592	CcSEcCtD
Metronidazole—Sweating—Epirubicin—urinary bladder cancer	0.000284	0.000591	CcSEcCtD
Metronidazole—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000284	0.000591	CcSEcCtD
Metronidazole—Asthenia—Gemcitabine—urinary bladder cancer	0.000283	0.00059	CcSEcCtD
Metronidazole—Pharyngitis—Methotrexate—urinary bladder cancer	0.000282	0.000587	CcSEcCtD
Metronidazole—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000281	0.000584	CcSEcCtD
Metronidazole—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00028	0.000583	CcSEcCtD
Metronidazole—Pruritus—Gemcitabine—urinary bladder cancer	0.000279	0.000581	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000279	0.0068	CbGpPWpGaD
Metronidazole—Nausea—Thiotepa—urinary bladder cancer	0.000279	0.00058	CcSEcCtD
Metronidazole—Sinusitis—Epirubicin—urinary bladder cancer	0.000278	0.000579	CcSEcCtD
Metronidazole—Feeling abnormal—Etoposide—urinary bladder cancer	0.000278	0.000578	CcSEcCtD
Metronidazole—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000277	0.000576	CcSEcCtD
Metronidazole—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000276	0.000574	CcSEcCtD
Metronidazole—Pruritus—Fluorouracil—urinary bladder cancer	0.000275	0.000572	CcSEcCtD
Metronidazole—Drowsiness—Doxorubicin—urinary bladder cancer	0.000274	0.000571	CcSEcCtD
Metronidazole—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000274	0.000571	CcSEcCtD
Metronidazole—Infestation—Doxorubicin—urinary bladder cancer	0.000274	0.000571	CcSEcCtD
Metronidazole—Visual impairment—Methotrexate—urinary bladder cancer	0.000274	0.00057	CcSEcCtD
Metronidazole—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000272	0.000566	CcSEcCtD
Metronidazole—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000271	0.000564	CcSEcCtD
Metronidazole—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00027	0.000562	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000269	0.00655	CbGpPWpGaD
Metronidazole—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000269	0.000559	CcSEcCtD
Metronidazole—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000269	0.000559	CcSEcCtD
Metronidazole—Urticaria—Etoposide—urinary bladder cancer	0.000268	0.000557	CcSEcCtD
Metronidazole—Stomatitis—Doxorubicin—urinary bladder cancer	0.000267	0.000556	CcSEcCtD
Metronidazole—Jaundice—Doxorubicin—urinary bladder cancer	0.000267	0.000556	CcSEcCtD
Metronidazole—Rhinitis—Epirubicin—urinary bladder cancer	0.000267	0.000555	CcSEcCtD
Metronidazole—Abdominal pain—Etoposide—urinary bladder cancer	0.000267	0.000555	CcSEcCtD
Metronidazole—Body temperature increased—Etoposide—urinary bladder cancer	0.000267	0.000555	CcSEcCtD
Metronidazole—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000267	0.000555	CcSEcCtD
Metronidazole—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000267	0.000555	CcSEcCtD
Metronidazole—Hepatitis—Epirubicin—urinary bladder cancer	0.000266	0.000554	CcSEcCtD
Metronidazole—Eye disorder—Methotrexate—urinary bladder cancer	0.000266	0.000553	CcSEcCtD
Metronidazole—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000266	0.000553	CcSEcCtD
Metronidazole—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000265	0.00646	CbGpPWpGaD
Metronidazole—Tinnitus—Methotrexate—urinary bladder cancer	0.000265	0.000552	CcSEcCtD
Metronidazole—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000265	0.000551	CcSEcCtD
Metronidazole—Asthenia—Cisplatin—urinary bladder cancer	0.000264	0.00055	CcSEcCtD
Metronidazole—Pharyngitis—Epirubicin—urinary bladder cancer	0.000264	0.00055	CcSEcCtD
Metronidazole—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000264	0.000549	CcSEcCtD
Metronidazole—Sweating—Doxorubicin—urinary bladder cancer	0.000263	0.000547	CcSEcCtD
Metronidazole—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000261	0.000544	CcSEcCtD
Metronidazole—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000259	0.00054	CcSEcCtD
Metronidazole—Angiopathy—Methotrexate—urinary bladder cancer	0.000258	0.000537	CcSEcCtD
Metronidazole—Sinusitis—Doxorubicin—urinary bladder cancer	0.000257	0.000535	CcSEcCtD
Metronidazole—Immune system disorder—Methotrexate—urinary bladder cancer	0.000257	0.000534	CcSEcCtD
Metronidazole—Dizziness—Fluorouracil—urinary bladder cancer	0.000257	0.000534	CcSEcCtD
Metronidazole—Visual impairment—Epirubicin—urinary bladder cancer	0.000256	0.000534	CcSEcCtD
Metronidazole—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000256	0.000533	CcSEcCtD
Metronidazole—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000256	0.000533	CcSEcCtD
Metronidazole—Diarrhoea—Cisplatin—urinary bladder cancer	0.000252	0.000524	CcSEcCtD
Metronidazole—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000252	0.000523	CcSEcCtD
Metronidazole—Vomiting—Gemcitabine—urinary bladder cancer	0.000251	0.000522	CcSEcCtD
Metronidazole—Mental disorder—Methotrexate—urinary bladder cancer	0.000249	0.000518	CcSEcCtD
Metronidazole—Rash—Gemcitabine—urinary bladder cancer	0.000249	0.000518	CcSEcCtD
Metronidazole—Dermatitis—Gemcitabine—urinary bladder cancer	0.000249	0.000518	CcSEcCtD
Metronidazole—Eye disorder—Epirubicin—urinary bladder cancer	0.000249	0.000517	CcSEcCtD
Metronidazole—Hypersensitivity—Etoposide—urinary bladder cancer	0.000248	0.000517	CcSEcCtD
Metronidazole—Tinnitus—Epirubicin—urinary bladder cancer	0.000248	0.000516	CcSEcCtD
Metronidazole—Erythema—Methotrexate—urinary bladder cancer	0.000247	0.000515	CcSEcCtD
Metronidazole—Headache—Gemcitabine—urinary bladder cancer	0.000247	0.000515	CcSEcCtD
Metronidazole—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000247	0.000514	CcSEcCtD
Metronidazole—Flushing—Epirubicin—urinary bladder cancer	0.000247	0.000514	CcSEcCtD
Metronidazole—Vomiting—Fluorouracil—urinary bladder cancer	0.000247	0.000514	CcSEcCtD
Metronidazole—Rhinitis—Doxorubicin—urinary bladder cancer	0.000247	0.000514	CcSEcCtD
Metronidazole—Hepatitis—Doxorubicin—urinary bladder cancer	0.000246	0.000512	CcSEcCtD
Metronidazole—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000245	0.00051	CcSEcCtD
Metronidazole—Rash—Fluorouracil—urinary bladder cancer	0.000245	0.000509	CcSEcCtD
Metronidazole—Dermatitis—Fluorouracil—urinary bladder cancer	0.000245	0.000509	CcSEcCtD
Metronidazole—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000244	0.000508	CcSEcCtD
Metronidazole—Headache—Fluorouracil—urinary bladder cancer	0.000243	0.000506	CcSEcCtD
Metronidazole—Dysgeusia—Methotrexate—urinary bladder cancer	0.000242	0.000504	CcSEcCtD
Metronidazole—Asthenia—Etoposide—urinary bladder cancer	0.000242	0.000503	CcSEcCtD
Metronidazole—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000242	0.000503	CcSEcCtD
Metronidazole—Angiopathy—Epirubicin—urinary bladder cancer	0.000241	0.000502	CcSEcCtD
Metronidazole—Immune system disorder—Epirubicin—urinary bladder cancer	0.00024	0.0005	CcSEcCtD
Metronidazole—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00024	0.000499	CcSEcCtD
Metronidazole—Back pain—Methotrexate—urinary bladder cancer	0.000239	0.000498	CcSEcCtD
Metronidazole—Pruritus—Etoposide—urinary bladder cancer	0.000239	0.000496	CcSEcCtD
Metronidazole—Visual impairment—Doxorubicin—urinary bladder cancer	0.000237	0.000494	CcSEcCtD
Metronidazole—Nausea—Gemcitabine—urinary bladder cancer	0.000235	0.000488	CcSEcCtD
Metronidazole—Vomiting—Cisplatin—urinary bladder cancer	0.000234	0.000487	CcSEcCtD
Metronidazole—Vision blurred—Methotrexate—urinary bladder cancer	0.000233	0.000485	CcSEcCtD
Metronidazole—Mental disorder—Epirubicin—urinary bladder cancer	0.000233	0.000485	CcSEcCtD
Metronidazole—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000233	0.000484	CcSEcCtD
Metronidazole—Rash—Cisplatin—urinary bladder cancer	0.000232	0.000483	CcSEcCtD
Metronidazole—Dermatitis—Cisplatin—urinary bladder cancer	0.000232	0.000483	CcSEcCtD
Metronidazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000232	0.00564	CbGpPWpGaD
Metronidazole—Erythema—Epirubicin—urinary bladder cancer	0.000232	0.000482	CcSEcCtD
Metronidazole—Diarrhoea—Etoposide—urinary bladder cancer	0.000231	0.00048	CcSEcCtD
Metronidazole—Nausea—Fluorouracil—urinary bladder cancer	0.000231	0.00048	CcSEcCtD
Metronidazole—Eye disorder—Doxorubicin—urinary bladder cancer	0.00023	0.000479	CcSEcCtD
Metronidazole—Tinnitus—Doxorubicin—urinary bladder cancer	0.00023	0.000478	CcSEcCtD
Metronidazole—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000228	0.000475	CcSEcCtD
Metronidazole—Flushing—Doxorubicin—urinary bladder cancer	0.000228	0.000475	CcSEcCtD
Metronidazole—Flatulence—Epirubicin—urinary bladder cancer	0.000228	0.000475	CcSEcCtD
Metronidazole—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000227	0.00554	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000227	0.00553	CbGpPWpGaD
Metronidazole—Dysgeusia—Epirubicin—urinary bladder cancer	0.000227	0.000472	CcSEcCtD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000224	0.00546	CbGpPWpGaD
Metronidazole—Back pain—Epirubicin—urinary bladder cancer	0.000224	0.000466	CcSEcCtD
Metronidazole—Angiopathy—Doxorubicin—urinary bladder cancer	0.000223	0.000465	CcSEcCtD
Metronidazole—Malaise—Methotrexate—urinary bladder cancer	0.000223	0.000464	CcSEcCtD
Metronidazole—Dizziness—Etoposide—urinary bladder cancer	0.000223	0.000464	CcSEcCtD
Metronidazole—Muscle spasms—Epirubicin—urinary bladder cancer	0.000223	0.000463	CcSEcCtD
Metronidazole—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000222	0.000463	CcSEcCtD
Metronidazole—Vertigo—Methotrexate—urinary bladder cancer	0.000222	0.000463	CcSEcCtD
Metronidazole—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000222	0.000462	CcSEcCtD
Metronidazole—Leukopenia—Methotrexate—urinary bladder cancer	0.000222	0.000461	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.00022	0.00535	CbGpPWpGaD
Metronidazole—Nausea—Cisplatin—urinary bladder cancer	0.000219	0.000455	CcSEcCtD
Metronidazole—Vision blurred—Epirubicin—urinary bladder cancer	0.000218	0.000454	CcSEcCtD
Metronidazole—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000217	0.00528	CbGpPWpGaD
Metronidazole—Mental disorder—Doxorubicin—urinary bladder cancer	0.000216	0.000449	CcSEcCtD
Metronidazole—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000215	0.00525	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000215	0.00525	CbGpPWpGaD
Metronidazole—Convulsion—Methotrexate—urinary bladder cancer	0.000214	0.000446	CcSEcCtD
Metronidazole—Vomiting—Etoposide—urinary bladder cancer	0.000214	0.000446	CcSEcCtD
Metronidazole—Erythema—Doxorubicin—urinary bladder cancer	0.000214	0.000446	CcSEcCtD
Metronidazole—Rash—Etoposide—urinary bladder cancer	0.000213	0.000442	CcSEcCtD
Metronidazole—Dermatitis—Etoposide—urinary bladder cancer	0.000212	0.000442	CcSEcCtD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000212	0.00517	CbGpPWpGaD
Metronidazole—Headache—Etoposide—urinary bladder cancer	0.000211	0.00044	CcSEcCtD
Metronidazole—Flatulence—Doxorubicin—urinary bladder cancer	0.000211	0.000439	CcSEcCtD
Metronidazole—Arthralgia—Methotrexate—urinary bladder cancer	0.000211	0.000438	CcSEcCtD
Metronidazole—Chest pain—Methotrexate—urinary bladder cancer	0.000211	0.000438	CcSEcCtD
Metronidazole—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00021	0.000437	CcSEcCtD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000209	0.000435	CcSEcCtD
Metronidazole—Malaise—Epirubicin—urinary bladder cancer	0.000209	0.000435	CcSEcCtD
Metronidazole—Vertigo—Epirubicin—urinary bladder cancer	0.000208	0.000433	CcSEcCtD
Metronidazole—Syncope—Epirubicin—urinary bladder cancer	0.000208	0.000432	CcSEcCtD
Metronidazole—Leukopenia—Epirubicin—urinary bladder cancer	0.000207	0.000431	CcSEcCtD
Metronidazole—Back pain—Doxorubicin—urinary bladder cancer	0.000207	0.000431	CcSEcCtD
Metronidazole—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000206	0.000429	CcSEcCtD
Metronidazole—Palpitations—Epirubicin—urinary bladder cancer	0.000205	0.000426	CcSEcCtD
Metronidazole—Confusional state—Methotrexate—urinary bladder cancer	0.000204	0.000424	CcSEcCtD
Metronidazole—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000204	0.000424	CcSEcCtD
Metronidazole—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000202	0.00042	CcSEcCtD
Metronidazole—Vision blurred—Doxorubicin—urinary bladder cancer	0.000202	0.00042	CcSEcCtD
Metronidazole—Convulsion—Epirubicin—urinary bladder cancer	0.000201	0.000418	CcSEcCtD
Metronidazole—Infection—Methotrexate—urinary bladder cancer	0.000201	0.000418	CcSEcCtD
Metronidazole—Nausea—Etoposide—urinary bladder cancer	0.0002	0.000417	CcSEcCtD
Metronidazole—Hypertension—Epirubicin—urinary bladder cancer	0.0002	0.000416	CcSEcCtD
Metronidazole—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000198	0.000412	CcSEcCtD
Metronidazole—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000198	0.000412	CcSEcCtD
Metronidazole—Arthralgia—Epirubicin—urinary bladder cancer	0.000197	0.00041	CcSEcCtD
Metronidazole—Chest pain—Epirubicin—urinary bladder cancer	0.000197	0.00041	CcSEcCtD
Metronidazole—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000197	0.0048	CbGpPWpGaD
Metronidazole—Skin disorder—Methotrexate—urinary bladder cancer	0.000196	0.000408	CcSEcCtD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000196	0.000407	CcSEcCtD
Metronidazole—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000195	0.000406	CcSEcCtD
Metronidazole—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000194	0.00473	CbGpPWpGaD
Metronidazole—Malaise—Doxorubicin—urinary bladder cancer	0.000193	0.000402	CcSEcCtD
Metronidazole—Dry mouth—Epirubicin—urinary bladder cancer	0.000193	0.000401	CcSEcCtD
Metronidazole—Vertigo—Doxorubicin—urinary bladder cancer	0.000193	0.000401	CcSEcCtD
Metronidazole—Anorexia—Methotrexate—urinary bladder cancer	0.000193	0.000401	CcSEcCtD
Metronidazole—Syncope—Doxorubicin—urinary bladder cancer	0.000192	0.0004	CcSEcCtD
Metronidazole—Leukopenia—Doxorubicin—urinary bladder cancer	0.000192	0.000399	CcSEcCtD
Metronidazole—Confusional state—Epirubicin—urinary bladder cancer	0.000191	0.000397	CcSEcCtD
Metronidazole—Palpitations—Doxorubicin—urinary bladder cancer	0.000189	0.000394	CcSEcCtD
Metronidazole—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000189	0.000393	CcSEcCtD
Metronidazole—Oedema—Epirubicin—urinary bladder cancer	0.000189	0.000393	CcSEcCtD
Metronidazole—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000188	0.000392	CcSEcCtD
Metronidazole—Infection—Epirubicin—urinary bladder cancer	0.000188	0.000391	CcSEcCtD
Metronidazole—Shock—Epirubicin—urinary bladder cancer	0.000186	0.000387	CcSEcCtD
Metronidazole—Convulsion—Doxorubicin—urinary bladder cancer	0.000186	0.000386	CcSEcCtD
Metronidazole—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000185	0.000386	CcSEcCtD
Metronidazole—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000185	0.000385	CcSEcCtD
Metronidazole—Hypertension—Doxorubicin—urinary bladder cancer	0.000185	0.000385	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000184	0.000383	CcSEcCtD
Metronidazole—Skin disorder—Epirubicin—urinary bladder cancer	0.000184	0.000382	CcSEcCtD
Metronidazole—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000183	0.00038	CcSEcCtD
Metronidazole—Insomnia—Methotrexate—urinary bladder cancer	0.000183	0.00038	CcSEcCtD
Metronidazole—Arthralgia—Doxorubicin—urinary bladder cancer	0.000182	0.00038	CcSEcCtD
Metronidazole—Chest pain—Doxorubicin—urinary bladder cancer	0.000182	0.00038	CcSEcCtD
Metronidazole—Paraesthesia—Methotrexate—urinary bladder cancer	0.000181	0.000377	CcSEcCtD
Metronidazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000181	0.000377	CcSEcCtD
Metronidazole—Anorexia—Epirubicin—urinary bladder cancer	0.00018	0.000375	CcSEcCtD
Metronidazole—Somnolence—Methotrexate—urinary bladder cancer	0.00018	0.000374	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000179	0.00436	CbGpPWpGaD
Metronidazole—Dry mouth—Doxorubicin—urinary bladder cancer	0.000178	0.000371	CcSEcCtD
Metronidazole—Dyspepsia—Methotrexate—urinary bladder cancer	0.000178	0.00037	CcSEcCtD
Metronidazole—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000177	0.00432	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000176	0.0043	CbGpPWpGaD
Metronidazole—Confusional state—Doxorubicin—urinary bladder cancer	0.000176	0.000367	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000176	0.00428	CbGpPWpGaD
Metronidazole—Decreased appetite—Methotrexate—urinary bladder cancer	0.000176	0.000365	CcSEcCtD
Metronidazole—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000175	0.00426	CbGpPWpGaD
Metronidazole—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000175	0.000364	CcSEcCtD
Metronidazole—Oedema—Doxorubicin—urinary bladder cancer	0.000175	0.000364	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000174	0.000363	CcSEcCtD
Metronidazole—Fatigue—Methotrexate—urinary bladder cancer	0.000174	0.000362	CcSEcCtD
Metronidazole—Infection—Doxorubicin—urinary bladder cancer	0.000174	0.000362	CcSEcCtD
Metronidazole—Pain—Methotrexate—urinary bladder cancer	0.000173	0.000359	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000172	0.000358	CcSEcCtD
Metronidazole—Shock—Doxorubicin—urinary bladder cancer	0.000172	0.000358	CcSEcCtD
Metronidazole—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000172	0.000357	CcSEcCtD
Metronidazole—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000171	0.000356	CcSEcCtD
Metronidazole—Insomnia—Epirubicin—urinary bladder cancer	0.000171	0.000356	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.00017	0.00415	CbGpPWpGaD
Metronidazole—Skin disorder—Doxorubicin—urinary bladder cancer	0.00017	0.000354	CcSEcCtD
Metronidazole—Paraesthesia—Epirubicin—urinary bladder cancer	0.00017	0.000353	CcSEcCtD
Metronidazole—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000169	0.000352	CcSEcCtD
Metronidazole—Somnolence—Epirubicin—urinary bladder cancer	0.000168	0.00035	CcSEcCtD
Metronidazole—Anorexia—Doxorubicin—urinary bladder cancer	0.000167	0.000347	CcSEcCtD
Metronidazole—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000166	0.000346	CcSEcCtD
Metronidazole—Dyspepsia—Epirubicin—urinary bladder cancer	0.000166	0.000346	CcSEcCtD
Metronidazole—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000165	0.000344	CcSEcCtD
Metronidazole—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000164	0.00401	CbGpPWpGaD
Metronidazole—Decreased appetite—Epirubicin—urinary bladder cancer	0.000164	0.000342	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000163	0.00034	CcSEcCtD
Metronidazole—Fatigue—Epirubicin—urinary bladder cancer	0.000163	0.000339	CcSEcCtD
Metronidazole—Pain—Epirubicin—urinary bladder cancer	0.000162	0.000336	CcSEcCtD
Metronidazole—Constipation—Epirubicin—urinary bladder cancer	0.000162	0.000336	CcSEcCtD
Metronidazole—Urticaria—Methotrexate—urinary bladder cancer	0.00016	0.000334	CcSEcCtD
Metronidazole—Abdominal pain—Methotrexate—urinary bladder cancer	0.00016	0.000332	CcSEcCtD
Metronidazole—Body temperature increased—Methotrexate—urinary bladder cancer	0.00016	0.000332	CcSEcCtD
Metronidazole—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000159	0.000332	CcSEcCtD
Metronidazole—Insomnia—Doxorubicin—urinary bladder cancer	0.000158	0.000329	CcSEcCtD
Metronidazole—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000157	0.000327	CcSEcCtD
Metronidazole—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000156	0.000324	CcSEcCtD
Metronidazole—Somnolence—Doxorubicin—urinary bladder cancer	0.000155	0.000324	CcSEcCtD
Metronidazole—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000155	0.000322	CcSEcCtD
Metronidazole—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000154	0.00032	CcSEcCtD
Metronidazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000153	0.00372	CbGpPWpGaD
Metronidazole—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000152	0.000316	CcSEcCtD
Metronidazole—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000151	0.000314	CcSEcCtD
Metronidazole—Fatigue—Doxorubicin—urinary bladder cancer	0.000151	0.000314	CcSEcCtD
Metronidazole—Urticaria—Epirubicin—urinary bladder cancer	0.00015	0.000312	CcSEcCtD
Metronidazole—Constipation—Doxorubicin—urinary bladder cancer	0.00015	0.000311	CcSEcCtD
Metronidazole—Pain—Doxorubicin—urinary bladder cancer	0.00015	0.000311	CcSEcCtD
Metronidazole—Abdominal pain—Epirubicin—urinary bladder cancer	0.000149	0.000311	CcSEcCtD
Metronidazole—Body temperature increased—Epirubicin—urinary bladder cancer	0.000149	0.000311	CcSEcCtD
Metronidazole—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000149	0.00031	CcSEcCtD
Metronidazole—Asthenia—Methotrexate—urinary bladder cancer	0.000145	0.000302	CcSEcCtD
Metronidazole—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000144	0.0003	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000143	0.00348	CbGpPWpGaD
Metronidazole—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000143	0.000298	CcSEcCtD
Metronidazole—Pruritus—Methotrexate—urinary bladder cancer	0.000143	0.000297	CcSEcCtD
Metronidazole—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000139	0.00029	CcSEcCtD
Metronidazole—Urticaria—Doxorubicin—urinary bladder cancer	0.000139	0.000289	CcSEcCtD
Metronidazole—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000139	0.00338	CbGpPWpGaD
Metronidazole—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000138	0.000288	CcSEcCtD
Metronidazole—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000138	0.000288	CcSEcCtD
Metronidazole—Diarrhoea—Methotrexate—urinary bladder cancer	0.000138	0.000288	CcSEcCtD
Metronidazole—Asthenia—Epirubicin—urinary bladder cancer	0.000136	0.000282	CcSEcCtD
Metronidazole—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000134	0.00326	CbGpPWpGaD
Metronidazole—Pruritus—Epirubicin—urinary bladder cancer	0.000134	0.000278	CcSEcCtD
Metronidazole—Dizziness—Methotrexate—urinary bladder cancer	0.000134	0.000278	CcSEcCtD
Metronidazole—Diarrhoea—Epirubicin—urinary bladder cancer	0.000129	0.000269	CcSEcCtD
Metronidazole—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000129	0.000268	CcSEcCtD
Metronidazole—Vomiting—Methotrexate—urinary bladder cancer	0.000128	0.000267	CcSEcCtD
Metronidazole—Rash—Methotrexate—urinary bladder cancer	0.000127	0.000265	CcSEcCtD
Metronidazole—Dermatitis—Methotrexate—urinary bladder cancer	0.000127	0.000265	CcSEcCtD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000127	0.00309	CbGpPWpGaD
Metronidazole—Headache—Methotrexate—urinary bladder cancer	0.000127	0.000263	CcSEcCtD
Metronidazole—Asthenia—Doxorubicin—urinary bladder cancer	0.000125	0.000261	CcSEcCtD
Metronidazole—Dizziness—Epirubicin—urinary bladder cancer	0.000125	0.00026	CcSEcCtD
Metronidazole—Pruritus—Doxorubicin—urinary bladder cancer	0.000124	0.000257	CcSEcCtD
Metronidazole—Vomiting—Epirubicin—urinary bladder cancer	0.00012	0.00025	CcSEcCtD
Metronidazole—Nausea—Methotrexate—urinary bladder cancer	0.00012	0.00025	CcSEcCtD
Metronidazole—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00012	0.000249	CcSEcCtD
Metronidazole—Rash—Epirubicin—urinary bladder cancer	0.000119	0.000248	CcSEcCtD
Metronidazole—Dermatitis—Epirubicin—urinary bladder cancer	0.000119	0.000248	CcSEcCtD
Metronidazole—Headache—Epirubicin—urinary bladder cancer	0.000118	0.000246	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000118	0.00288	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000118	0.00287	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000117	0.00284	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000116	0.00283	CbGpPWpGaD
Metronidazole—Dizziness—Doxorubicin—urinary bladder cancer	0.000116	0.000241	CcSEcCtD
Metronidazole—Nausea—Epirubicin—urinary bladder cancer	0.000112	0.000234	CcSEcCtD
Metronidazole—Vomiting—Doxorubicin—urinary bladder cancer	0.000111	0.000231	CcSEcCtD
Metronidazole—Rash—Doxorubicin—urinary bladder cancer	0.00011	0.000229	CcSEcCtD
Metronidazole—Dermatitis—Doxorubicin—urinary bladder cancer	0.00011	0.000229	CcSEcCtD
Metronidazole—Headache—Doxorubicin—urinary bladder cancer	0.00011	0.000228	CcSEcCtD
Metronidazole—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000109	0.00264	CbGpPWpGaD
Metronidazole—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000107	0.00261	CbGpPWpGaD
Metronidazole—Nausea—Doxorubicin—urinary bladder cancer	0.000104	0.000216	CcSEcCtD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000103	0.00252	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	9.62e-05	0.00234	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.48e-05	0.00231	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	9.43e-05	0.0023	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	9.15e-05	0.00223	CbGpPWpGaD
Metronidazole—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	8.84e-05	0.00215	CbGpPWpGaD
Metronidazole—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.72e-05	0.00212	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	7.24e-05	0.00176	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	6.86e-05	0.00167	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—NAT1—urinary bladder cancer	6.86e-05	0.00167	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.75e-05	0.00164	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.34e-05	0.00154	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	6.28e-05	0.00153	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.25e-05	0.00152	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	5.89e-05	0.00143	CbGpPWpGaD
Metronidazole—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.83e-05	0.00142	CbGpPWpGaD
Metronidazole—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.75e-05	0.0014	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	5.65e-05	0.00138	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	5.58e-05	0.00136	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—NAT1—urinary bladder cancer	5.58e-05	0.00136	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.49e-05	0.00134	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	5.34e-05	0.0013	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	5.2e-05	0.00127	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	5.11e-05	0.00124	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	4.6e-05	0.00112	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	4.34e-05	0.00106	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	4.23e-05	0.00103	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.17e-05	0.00102	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—TYMP—urinary bladder cancer	4.16e-05	0.00101	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.99e-05	0.000973	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.88e-05	0.000946	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—NAT2—urinary bladder cancer	3.76e-05	0.000916	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.68e-05	0.000897	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.68e-05	0.000897	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.39e-05	0.000827	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—TYMP—urinary bladder cancer	3.38e-05	0.000824	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.37e-05	0.00082	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.25e-05	0.000792	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—RRM2—urinary bladder cancer	3.25e-05	0.00079	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—NAT2—urinary bladder cancer	3.06e-05	0.000745	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.03e-05	0.000739	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	3.01e-05	0.000732	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ENO2—urinary bladder cancer	3.01e-05	0.000732	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.99e-05	0.000728	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.92e-05	0.00071	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.87e-05	0.000699	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.86e-05	0.000698	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.79e-05	0.00068	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.64e-05	0.000643	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ENO2—urinary bladder cancer	2.45e-05	0.000596	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	2.45e-05	0.000596	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.43e-05	0.000592	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2.42e-05	0.00059	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	2.37e-05	0.000578	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.35e-05	0.000573	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.34e-05	0.000569	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.23e-05	0.000544	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.05e-05	0.000499	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.02e-05	0.000492	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.02e-05	0.000492	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.97e-05	0.00048	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.95e-05	0.000476	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.91e-05	0.000466	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.88e-05	0.000458	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.86e-05	0.000452	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.86e-05	0.000452	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.78e-05	0.000433	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.75e-05	0.000425	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.74e-05	0.000424	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.67e-05	0.000406	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.64e-05	0.000401	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.64e-05	0.0004	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.61e-05	0.000393	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.61e-05	0.000393	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.59e-05	0.000388	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.56e-05	0.000381	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.53e-05	0.000372	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.51e-05	0.000368	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.51e-05	0.000368	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.45e-05	0.000353	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.42e-05	0.000346	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.34e-05	0.000325	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.33e-05	0.000324	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.3e-05	0.000317	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.28e-05	0.000311	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.08e-05	0.000264	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.08e-05	0.000264	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.05e-05	0.000255	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.04e-05	0.000253	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.01e-05	0.000246	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	9.97e-06	0.000243	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	9.97e-06	0.000243	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—GPX1—urinary bladder cancer	9.54e-06	0.000232	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	9.37e-06	0.000228	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—PTEN—urinary bladder cancer	9.13e-06	0.000222	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	8.81e-06	0.000215	CbGpPWpGaD
Metronidazole—CYP2C8—Metabolism—EP300—urinary bladder cancer	8.71e-06	0.000212	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	8.52e-06	0.000208	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—PTEN—urinary bladder cancer	7.43e-06	0.000181	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.14e-06	0.000174	CbGpPWpGaD
Metronidazole—CYP2C9—Metabolism—EP300—urinary bladder cancer	7.09e-06	0.000173	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.86e-06	0.000167	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	5.62e-06	0.000137	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.9e-06	0.000119	CbGpPWpGaD
Metronidazole—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.67e-06	0.000114	CbGpPWpGaD
